Added to YB: 2025-12-23
Pitch date: 2025-12-19
GSK [bullish]
GSK plc
+0.08%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 73.1B
Pitch Price
GBP 18.09
Price Target
N/A
Dividend
3.35%
EV/EBITDA
8.96
P/E
13.71
EV/Sales
2.71
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 19/12/2025 - GSK – Pipeline progress
GSK (update): Depemokimab approved in UK & US for severe asthma (260M patients globally, 2M in US). EU approval expected early 2026, Japan/China reviewing. 62 medicines/vaccines in pipeline, 16 in Phase III. Trades 10.1x 2026 P/E, 3.8% yield - pipeline potential undervalued.
Read full article (1 min)